The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or
stimulate its activity is the basis for the rapid growth and development of the therapeutic …

Although the identification of cancer stem cells as therapeutic targets is now actively being
pursued in many human malignancies, the leukemic stem cells in acute myeloid leukemia …

Background The results of the addition of gemtuzumab ozogamicin, an anti-CD33 antibody
conjugate, to the standard treatment for patients with acute myeloid leukaemia in phase 3 …

Purpose: The graft versus leukemia effect by natural killer (NK) cells prevents relapse
following hematopoietic stem cell transplantation. We determined whether a novel bispecific …

CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …

Accumulating evidence indicates that many human cancers are organized as a cellular
hierarchy initiated and maintained by self-renewing cancer stem cells. This cancer stem cell …

Background: Acute myeloid leukemia (AML) is a clonal disease characterized by the
proliferation and accumulation of myeloid progenitor cells in the bone marrow, which …

Monoclonal antibodies (mAb) are emerging as one of the major class of therapeutic agents
in the treatment of many human diseases, in particular in cancer and immunological …

Background Cytokine-induced killer cells are ex vivo-expanded cells with potent antitumor
activity. The infusion of cytokine-induced killer cells in patients with acute myeloid leukemia …

Acute myeloid leukemia (AML) patients show high relapse rates and some develop
conventional chemotherapy resistance. Leukemia Stem Cells (LSCs) are the main player for …